Hydrocortisone

A Gynecologist’s Guide to Maintaining Vaginal Health on Spring Break

Retrieved on: 
Tuesday, February 28, 2023
Other Communications, Teens, Destinations, Travel, Marketing, Communications, Other Health, Other Retail, Other Education, Vacation, Specialty, Infectious Diseases, Convenience Store, University, Education, Other Consumer, Cosmetics, Retail, Home Goods, Women, Medical Supplies, General Health, Health, Online Retail, Consumer, Department Stores, Generation Z, Skin, Perspiration, Weather, Aloe, Swimming, Chamomile, Bacteria, Irritation, Risk, Sensation, Pregnancy, Growth, Arm, Sand, Hydrocortisone, Environment, Exercise, Hammer, Vagina, STI, Itch, Water, Woman, Birth control

Spring is just around the corner, which means many women are planning to enjoy fun in the sun on spring break in the coming weeks.

Key Points: 
  • Spring is just around the corner, which means many women are planning to enjoy fun in the sun on spring break in the coming weeks.
  • To help women maintain their vaginal health on spring break, Maria Sophocles , M.D., gynecologist, Medical Director of Women’s Healthcare of Princeton, NJ, and host of Gynecollege™ , shares her expert advice.
  • “While it’s important to maintain vaginal health year-round, the vagina needs special attention at times when traveling and changes in weather.
  • “By following these simple tips, women can enjoy their spring break activities while staying comfortable and healthy.”
    Dr. Sophocles recommends the following tips to maintain vaginal health during spring break:
    Avoid re-wearing swimsuits: Because bacteria can accumulate in the fabric, it’s best to avoid re-wearing swimsuits without washing them first.

Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, MPH, Androstenedione, Infertility, Polycystic ovary syndrome, Hirsutism, CAH, DHEAS, Glucocorticoid, Safety, Pharmacokinetics, Degenerative disease, Risk, PD, GC, Partnership, Adolescence, Growth, Cyst, Patient, Observation, Hydrocortisone, Trial of the century, Clinical trial, Puberty, Disclosure, Investment, Dehydroepiandrosterone sulfate, Pharmaceutical industry, Birth control, PCOS, A4

“As we enter 2023, we are pleased to have recently announced our strategic partnership with Kaken Pharmaceutical to develop and commercialize tildacerfont in Japan,” said Javier Szwarcberg, M.D., MPH, Chief Executive Officer of Spruce Biosciences.

Key Points: 
  • “As we enter 2023, we are pleased to have recently announced our strategic partnership with Kaken Pharmaceutical to develop and commercialize tildacerfont in Japan,” said Javier Szwarcberg, M.D., MPH, Chief Executive Officer of Spruce Biosciences.
  • Phase 2 CAHptain Clinical Study in Pediatric Classic CAH: Spruce is investigating tildacerfont for the treatment of classic CAH in children.
  • Adrenal androgen overproduction is thought to contribute to the clinical manifestations of PCOS in some patients.
  • By reducing ACTH-stimulated adrenal androgen production, tildacerfont has the potential to treat the clinical sequelae of PCOS.

ZYMOX Enzyme-Based Pet Health Products Introduces New Products for Cats and Kittens

Retrieved on: 
Monday, October 17, 2022
Cream, Cat, Ear, Dermatology, Animal, Infection, TICA, Hydrocortisone, The International Cat Association, Health, Dermatophytosis, Acne, Mouth, Solution, Veterinary medicine, Skin

WESTMONT, Ill., Oct. 17, 2022 /PRNewswire/ -- Pet King Brands, Inc. announced they have expanded their veterinarian-recommended line of ZYMOX® Enzymatic Dermatology products to include three new products to provide relief of ear and skin conditions in cats and kittens. These new products will feature feline-focused packaging with images of cats and will include the prestigious Seal of Endorsement awarded by TICA, The International Cat Association.

Key Points: 
  • WESTMONT, Ill., Oct. 17, 2022 /PRNewswire/ -- Pet King Brands, Inc. announced they have expanded their veterinarian-recommended line of ZYMOX Enzymatic Dermatology products to include three new products to provide relief of ear and skin conditions in cats and kittens.
  • The line includes ZYMOX Enzymatic Ear Solution with 0.5% Hydrocortisone, ZYMOX Enzymatic Ear Cleanser, and the ZYMOX Enzymatic Topical Cream with 0.5% Hydrocortisone.
  • ZYMOX for Cats and Kittens has begun shipping and is available for purchase.
  • To learn more about the products, visit www.zymox.com
    Pet King Brands, the maker of ZYMOX Ear and Skin products, Oratene Brushless Oral Care, Equine Defense, and ZYLAFEN is a leader in veterinarian-approved pet products made in the USA.

EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody® in Switzerland

Retrieved on: 
Tuesday, April 26, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, MAA, ODD, Prednisone, Sleep, Osteoporosis, Adrenal insufficiency, Marketing, Adult, European Commission, Dexamethasone, Hypogonadism, Hypothyroidism, Adolescence, CAH, Congenital adrenal hyperplasia, Birth, Infertility, Degenerative disease, Death, Patient, Hydrocortisone, Birth defect, Puberty, Suffering, Medication package insert, Mortality, MHRA, Prednisolone, Marketing Authorisation Application, Product, Physician, Union, FDA, Male, Androgen, Risk, Interim, Therapy, Adrenal crisis, Pharmaceutical industry, Diurnal, Swissmedic

EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody as treatment for congenital adrenal hyperplasia (CAH) in Switzerland.

Key Points: 
  • EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody as treatment for congenital adrenal hyperplasia (CAH) in Switzerland.
  • Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Efmody in Switzerland.
  • The MAA submission to Swissmedic for Efmody will be based on the European regulatory dossier and published clinical trial data, with EffRx expecting potential market launch in Switzerland in 2024.
  • We are pleased to deepen our relationship with EffRx to include the distribution and marketing of Efmody in Switzerland.

Endpoint Health Announces Results from Retrospective Analyses Evaluating the Corticosteroid Response in Patients with Septic Shock, Based on Novel Gene Expression Scoring Model

Retrieved on: 
Wednesday, March 2, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Division, High-dependency unit, Therapy, Social media, Data, Critical care, Twitter, Distributive shock, Vasodilatory shock, BMJ Open, RNA, Septic shock, Diagnosis, Gene, Social, Hydrocortisone, Inflammatory bowel disease, Biology, Vasodilation, Safety, Disease, Food, Acute respiratory distress syndrome, Gene expression, Machine learning, Critical Care Medicine (journal), Blood pressure, Rheumatoid arthritis, United, FDA, US Foods, Blood, Patient, MD, Research, Health, Shock, Mortality, Intensive care unit, Dilation, Medical device, Pharmaceutical industry, SHOCK, Norepinephrine, Sepsis, Medscape, Burn, the Research, Septic Shock, Endpoint Health, Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, the Research, Septic Shock, Endpoint Health, THE RESEARCH, SEPTIC SHOCK, ENDPOINT HEALTH

This research is a meaningful step towards exploring the possibility that subgroups of septic shock patients may respond differently to hydrocortisone therapy depending on their biological characteristics.

Key Points: 
  • This research is a meaningful step towards exploring the possibility that subgroups of septic shock patients may respond differently to hydrocortisone therapy depending on their biological characteristics.
  • These latest findings further illustrate the potential of our proprietary AI and machine learning platform to inform personalized care for critically ill patients, based on electronic health data and gene expression scoring.
  • To identify unique biological subgroups of patients, the researchers conducted a retrospective analysis, pooling publicly available data from various gene expression datasets of patients with sepsis and septic shock.
  • The secondary outcome was the immunological response to hydrocortisone therapy.1 This outcome was assessed based on gene expression data from the Burn study.

Women's Healthcare of Princeton, NJ, OB/GYN Maria Sophocles, M.D. Says, "Put Vaginal Health First this V-Day"

Retrieved on: 
Friday, February 11, 2022
Women, Other Retail, Specialty, Other Health, Physical Therapy, Managed Care, General Health, Consumer, Health, Retail, Trichomoniasis, STI, Arousal, Chlamydia, Collection, Woman, Vagina, Vulva, Sex, STD, Eating, Infection, Moisturizer, Friction, Aloe, Personal lubricant, Pain, ULTRA, Condom, Chocolate, MD, PH, Love, Gonorrhea, Salt, Magnesium, Dry, Hydrocortisone, Medical director, Itch, Birth control, Gynaecology

Dont neglect vaginal health as it is the prelude not only to sexual intimacy but everyday comfort.

Key Points: 
  • Dont neglect vaginal health as it is the prelude not only to sexual intimacy but everyday comfort.
  • Women have the power to maintain their vaginal health just as all other parts of the body.
  • And, most times, all it takes is a quick trip to the drugstore, but youve got to know what to look for.
  • However, fancy fragranced bubble baths and salts often do more harm than good as they can upset vaginal pH.

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue

Retrieved on: 
Tuesday, January 18, 2022
Hydrocortisone, Prescription, Research, Forward-looking statement, NDA, Patient, Teva, EVP, AMAG, Pfizer, Private Securities Litigation Reform Act, AMAG Pharmaceuticals, Fast Track, Regulation of tobacco by the U.S. Food and Drug Administration, Antares, COVID-19, Testosterone, Adrenal crisis, Growth, NASDAQ, Risk, GLOBE, Development, Review, U.S. Securities and Exchange Commission, Industry, Marketing, Research and development, Company, Food, Communication, Annual report, FDA, MRCP, Genta (company), Security (finance), Terminology, Pharmaceutical industry, Sumatriptan

EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue.

Key Points: 
  • EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue.
  • A drug candidate that receives Fast Track designation is eligible for more frequent communication with the FDA throughout the drug development process and a rolling and/or priority review of its marketing application if relevant criteria are met.
  • We are very pleased that ATRS-1902 has received Fast Track designation from the FDA, a distinction that underscores the urgent need for an improved therapy for these patients who suffer from a potentially life-threatening situation.
  • Robert F. Apple, President and Chief Executive Officer of Antares Pharma, added, This designation by the FDA represents an important milestone for the clinical development of ATRS-1902.

Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

Retrieved on: 
Tuesday, January 11, 2022
Hydrocortisone, Prescription, Research, Forward-looking statement, NDA, Patient, Teva, EVP, AMAG, Pfizer, Private Securities Litigation Reform Act, AMAG Pharmaceuticals, Antares, COVID-19, Testosterone, Adrenal crisis, Growth, NASDAQ, Risk, GLOBE, Development, U.S. Securities and Exchange Commission, Vai, Industry, Research and development, Company, Annual report, FDA, MRCP, Genta (company), Security (finance), Trial of the century, Terminology, Pharmaceutical industry, Sumatriptan

EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis.

Key Points: 
  • EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis.
  • We are pleased that the results from this Phase I study support the advancement of ATRS-1902 to a pivotal clinical study which we anticipate starting in the second quarter of 2022.
  • Robert F. Apple, President and Chief Executive Officer of Antares Pharma, added, These positive results reinforce our commitment to improving the current standard of care for adrenal crisis patients and advancing our proprietary development pipeline.
  • As a leader in rescue pen technology, our recently developed Vai device allows for a simple injection for patients in crisis.

Global Hydrocortisone (CAS 50-23-7) Market Report 2021: Market Trends and Developments, Major Players & Main Downstream Sectors - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Health, Pharmaceutical, Industry, CAS, Renewable energy, Hydrocortisone

The "Hydrocortisone (CAS 50-23-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrocortisone (CAS 50-23-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrocortisone.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The fifth chapter deals with Hydrocortisone market trends and forecast, distinguish Hydrocortisone manufacturers and suppliers.

EffRx Obtains Swiss Marketing Authorization for Alkindi® for Paediatric Adrenocortical Insufficiency

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Capsule, ODD, ACTH, European Union, Adrenal crisis, Food, Senior, Union, Diurnal, US Foods, Hypopituitarism, Exocrine gland, Hydrocortisone, AI, Hypogonadism, Adrenal insufficiency, Metabolism, CAH, Adrenocorticotropic hormone, Death, Physician, Patient, Congenital adrenal hyperplasia, Risk, FDA, Pharmaceutical industry, Medical device, EffRx Pharmaceuticals SA, Diurnal Group plc, EFFRX PHARMACEUTICALS SA, DIURNAL GROUP PLC

EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Alkindi for the treatment of paediatric adrenocortical insufficiency (AI).

Key Points: 
  • EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Alkindi for the treatment of paediatric adrenocortical insufficiency (AI).
  • Alkindi, developed by Diurnal Group plc, is the first preparation of hydrocortisone specifically designed for use in children suffering from paediatric adrenocortical insufficiency (AI).
  • Alkindi is a patented, oral, immediate-release paediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children.
  • Alkindi is approved and marketed in the European Union and is the first preparation of hydrocortisone specifically designed for use in children suffering from AI.